Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 1/20 | 0.48 |
| ▸ | GSK3B | P49841 | 3/20 | 0.47 |
| ▸ | CLK1 | P49759 | 1/20 | 0.45 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.45 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.45 |
| ▸ | VNN1 | O95497 | 13/20 | 0.44 |
| ▸ | XDH | P47989 | 1/20 | 0.40 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.40 |
| ▸ | BTD | P43251 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5226711 | 0.85 | MAPK14 (0.50) | MAPK14GSK3BCLK1DYRK1ADYRK1B | |
| SCHEMBL5039012 | 0.80 | MAPK14 (0.48) | MAPK14GSK3BCLK1DYRK1ADYRK1B | |
| SCHEMBL5042587 | 0.80 | MAPT (0.63) | MAPK14GSK3BCLK1DYRK1ADYRK1B | |
| SCHEMBL4709783 | 0.77 | VNN1 (0.52) | MAPK14VNN1 | |
| SCHEMBL15106407 | 0.77 | ABCC9 (0.47) | MAPK14GSK3BCLK1DYRK1ADYRK1B | |
| SCHEMBL8304975 | 0.76 | MAPK14 (0.47) | MAPK14GSK3BCLK1DYRK1ADYRK1B | |
| SCHEMBL4709037 | 0.76 | VNN1 (0.51) | MAPK14GSK3BVNN1 | |
| Hydrochloric Acid SCHEMBL6771762 | 0.75 | PRSS1 (0.47) | — | |
| SCHEMBL4709546 | 0.75 | KDM4E (0.48) | MAPK14GSK3BVNN1 | |
| SCHEMBL4709399 | 0.75 | VNN1 (0.45) | MAPK14GSK3BCLK1DYRK1ADYRK1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6677369-B2 | CARBOXIMIDAMIDE DERIVATIVE ANTICOAGULANTS INHIBIT FACTOR XA | ELI LILLY AND COMPANY | 2004-01-13 | — | — | US | disclosed |
| US-20030195223-A1 | An anticoagulant, blood inhibitor of factor Xa, a N1-amidinebenzoyl- N2-benzoyl-1,2-benzenediamine derivatives; chemical intermediates | BEIGHT DOUGLAS WADE (US) | 2003-10-16 | — | — | US | disclosed |
| US-6417200-B1 | BLOOD COAGULATION FACTOR XA IN MAMMALS | ELI LILLY AND COMPANY | 2002-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195223-A1 | An anticoagulant, blood inhibitor of factor Xa, a N1-amidinebenzoyl- N2-benzoyl-1,2-benzenediamine derivatives; chemical intermediates | F12, F11, F2 | MAPK14 1598/4885GSK3B 625/4885CLK1 3653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.